Grech, Olivia
Sassani, Matilde
Terwindt, Gisela
Lavery, Gareth G.
Mollan, Susan P.
Sinclair, Alexandra J.
Funding for this research was provided by:
Brain Research UK
National Institute for Health Research (NIHR-CS-011-028)
Dutch Research Council
Dutch Brain Foundation
Wellcome Trust (104612/Z/14/Z)
Medical Research Council (MR/K015184/1)
Sir Joules Thorn Trust (Sir Jules Thorn Award for Biomedical Science)
Article History
Received: 29 July 2022
Accepted: 10 September 2022
First Online: 30 September 2022
Declarations
:
: Not applicable.
: Not applicable.
: O.G reports scientific consultancy fees from Invex therapeutics. G.T reports consultancy fees Novartis, Teva, Allergan, Lilly, Lundbeck, royalties from the Dutch Neurology Handbook, other from CGRP Education and Research Forum and presenter for webinars with Springer Media, Mednet, Ashfield MedComms, Remedica, Cygnea. S.P reports other Invex Therapeutics, other Heidelberg engineering; other from Chugai-Roche Ltd, other from Janssen, other from Allergan, other from Santen, other from Roche, other from Neurodiem, outside the submitted work. A.J.S reports consulting fees and stockholding with Invex therapeutics, during the conduct of the study. Other from Allergan, Amgen, Novartis and Cheisi All other authors declare no competing interests.